The discussion will covers several aspects of GLP-1 RA therapy including comparison to other first injectable therapies for T2DM, safety and efficacy of once-a-week GLP-1 RA.
Understand increased cardiovascular Risks with Type 2 Diabetes patients.
Understand different cardiovascular trials design and patient population distribution.
Understand the difference between primary and secondary CV protection.
Understand the results of recent CV trials for Once-weekly dulaglutide and its implications on T2D patients.